undamentalytics Newsletter
Sign in

Arrowhead Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Arrowhead Pharmaceuticals, Inc.'s operations generated $180m of cash; it spent $22.7m on capital projects, leaving free cash flow of $157m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Cash from operations−8−15−19−35−66−64−24−47173−96171−136−154−463180−59
Depreciation and amortisation02212333347911172224
Stock-based pay112610128812437712178746370
Capital spending00022481121224531771412316
Free cash flow−8−16−19−37−68−68−32−49161−108148−189−331−604157−75
Free cash flow after stock pay−9−17−21−43−78−80−40−57149−15171−310−409−67894−145
Shares issued51145173—52125761250000429241—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ARWR vs NRIXARWR vs RAREARWR vs MIRMARWR vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arrowhead Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arrowhead Pharmaceuticals, Inc.